CoChat

Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study

Salamun, Vesna, Jensterle, Mojca, Janez, Andrej, Vrtacnik Bokal, Eda · 2018 · European Journal of Endocrinology

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Objective Glucagon-like peptide-1 (GLP-1) has been investigated in regulation of reproductive system in animal models. The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet. Design A prospective randomized open-label study was conducted in 28 infertile obese PCOS patients (age: 31.07 ± 4.75, BMI: 36.7 ± 3.5 kg/m 2 , mean ± s.d. ). They were assigned to metformin (MET) 1000 mg BID or to MET 1000 mg BID combined with low-dose liraglutide 1.2 mg QD s.c. (COMBI) for 12 weeks. Ovarian stimulation protocol was started after a 4-week medication-free period. Methods The in vitro fertilization pregnancy rate (PR) was defined as the number of clinical pregnancies confirmed by ultrasound visualization of the fetal cardiac activity, divided by the total number of cycles performed or embryo transfers (ET). The spontaneous PR was followed for 12 months. Results Patients in the MET group on average lost 7.0 ± 6.0 kg ( P = 0.001) compared with 7.5 ± 3.9 kg in the COMBI group ( P < 0.001) with no significant between-treatment difference ( P = 0.246). The PR per ET was significantly higher in the COMBI (85.7%) compared with the MET (28.6%) group ( P = 0.03). The cumulative PR in the time frame of 12 months was 69.2% in the COMBI group compared to 35.7% in the MET group. Conclusions Preconception intervention with low-dose liraglutide added to metformin is superior to metformin alone in increasing PRs per ET and cumulative PRs in infertile obese women with PCOS, despite comparable weight reduction in both groups. A potential impact of liraglutide on the reproductive system needs further exploration, in particular the GLP-1 impact on endometrial quality and receptivity.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-18-0175

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Research works printed but not linked: 50

  1. 2014, Physical activity before IVF and ICSI cycles in infertile obese women: an observational cohort study, Reproductive BioMedicine Online, 29, 72, 10.1016/j.rbmo.2014.03.006 · DOI · Paper page
  2. 2017, Effect of a lifestyle intervention in obese infertile women on cardiometabolic health and quality of life: results of a randomised controlled trial
  3. 2000, Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling, Endocrinology, 2, 752
  4. 2005, Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males, European Journal of Clinical Investigation, 35, 565, 10.1111/j.1365-2362.2005.01542.x · DOI · Paper page
  5. 2014, Weight loss improves reproductive outcomes for obese women undergoing assisted reproductive technology: a randomised controlled trial, Clinical Obesity, 14, 792
  6. 1999, Leptin’s actions on the reproductive axis: perspectives and mechanisms, Biology of Reproduction, 60, 616
  7. 2009, Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides, Journal of Clinical Endocrinology and Metabolism, 94, 1843, 10.1210/jc.2008-1296 · DOI · Paper page
  8. 2012, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria, Human Reproduction, 27, 3067, 10.1093/humrep/des232 · DOI · Paper page
  9. PCOS, Special Interest Group The polycystic ovary syndrome : a position statement from the European of of https org, Society Endocrinology European Journal Endocrinology, 1
  10. 2018, Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial, Diabetes, Obesity and Metabolism, 20, 215, 10.1111/dom.13053 · DOI · Paper page
  11. 1985, Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/bf00280883 · DOI · Paper page
  12. 2017, Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential, Endocrine Connections, 6, 89, 10.1530/ec-16-0113 · DOI · Paper page
  13. 2015, Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes, Diabetic Medicine, 32, 29, 10.1111/dme.12726 · DOI · Paper page
  14. 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clinical Endocrinology, 87, 767, 10.1111/cen.13454 · DOI · Paper page
  15. 2014, Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin, European Journal of Endocrinology, 170, 451, 10.1530/eje-13-0797 · DOI · Paper page
  16. 2003, Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women, Diabetes Care, 26, 1413, 10.2337/diacare.26.5.1413 · DOI · Paper page
  17. 1998, Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line, Journal of Clinical Investigation, 101, 1334, 10.1172/jci610 · DOI · Paper page
  18. 2008, Central control of body weight and appetite, Journal of Clinical Endocrinology and Metabolism, 93, 37, 10.1210/jc.2008-1630 · DOI · Paper page
  19. 2015, Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats, Gynecological Endocrinology, 31, 196, 10.3109/09513590.2014.975686 · DOI · Paper page
  20. 2008, Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome, Journal of Clinical Endocrinology and Metabolism, 93, 2670, 10.1210/jc.2008-0115 · DOI · Paper page
  21. 2017, Impact of body mass index on outcomes of in vitro fertilization/intracytoplasmic sperm injection among polycystic ovarian syndrome patient, Journal of Assisted Reproduction and Genetics, 34, 61
  22. 2015, Risks associated with obesity in pregnancy for the mother and baby: a systematic review of reviews, Obesity Reviews, 16, 621, 10.1111/obr.12288 · DOI · Paper page
  23. PCOS, Special Interest Group The polycystic ovary syndrome : a position statement from the European of of https org, Society Endocrinology European Journal Endocrinology, 1
  24. 2005, A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance, Diabetes Care, 28, 451, 10.2337/diacare.28.2.451 · DOI · Paper page
  25. 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, Lancet Diabetes and Endocrinology, 6, 105, 10.1016/s2213-8587(17)30412-6 · DOI · Paper page
  26. 2005, Diabetes (db/db) mutation-induced endometrial epithelial lipoapoptosis: ultrastructural and cytochemical analysis of reproductive tract atrophy, Reproductive Biology and Endocrinology, 3, 15, 10.1186/1477-7827-3-15 · DOI · Paper page
  27. 2007, The management of insulin resistance in polycystic ovary syndrome, Trends in Endocrinology and Metabolism, 18, 273, 10.1016/j.tem.2007.08.001 · DOI · Paper page
  28. 2008, Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study, Human Reproduction, 23, 642, 10.1093/humrep/dem391 · DOI · Paper page
  29. 2007, Impact of obesity on the risk for polycystic ovary syndrome, Journal of Clinical Endocrinology and Metabolism, 93, 162
  30. 2014, Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome, Cochrane Database of Systematic Reviews, 11, CD006105
  31. 2017, Weight decrease improves live birth rates in obese women undergoing IVF: a pilot study, Reproductive BioMedicine Online, 35, 417, 10.1016/j.rbmo.2017.06.019 · DOI
  32. 2016, Successful pregnancy after improving insulin resistance with the glucagon-like peptide-1 analogue in a woman with polycystic ovary syndrome: a case report and review of the literature, Gynecologic and Obstetric Investigation, 81, 477, 10.1159/000446951 · DOI
  33. 2015, GLP-1 increases pre-ovulatory LH source and the number of mature follicles as well as synchronizing the onset of puberty in female rats, Endocrinology, 156, 4226, 10.1210/en.2014-1978 · DOI · Paper page
  34. 2014, Weight loss improves reproductive outcomes for obese women undergoing assisted reproductive technology: a randomised controlled trial, Clinical Obesity, 14, 792
  35. 2014, Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review, Obesity Reviews, 15, 839, 10.1111/obr.12217 · DOI · Paper page
  36. 2013, Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials, Reproductive BioMedicine Online, 120, 267
  37. 2017, Effect of a lifestyle intervention in obese infertile women on cardiometabolic health and quality of life: results of a randomised controlled trial
  38. 2011, Diet and IVF pilot study: short-term weight loss improves pregnancy rates in overweight/obese women undertaking IVF, Australian and New Zealand Journal of Obstetrics and Gynaecology, 51, 455, 10.1111/j.1479-828x.2011.01343.x · DOI · Paper page
  39. 2000, Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer, Fertility and Sterility, 73, 1155, 10.1016/s0015-0282(00)00518-5 · DOI · Paper page
  40. 2015, GLP-1 increases pre-ovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats, Endocrinology, 156, 4226, 10.1210/en.2014-1978 · DOI · Paper page
  41. 2009, Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis, Human Reproduction Update, 15, 57
  42. 1999, Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone, Journal of Clinical Endocrinology and Metabolism, 84, 1470
  43. 2007, Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome, Clinical endocrinology, 66, 513, 10.1111/j.1365-2265.2007.02764.x · DOI · Paper page
  44. 2003, Successful freezing and thawing of blastocysts cultured in sequential media using a modified method, Fertility and Sterility, 79, 1428, 10.1016/s0015-0282(03)00395-9 · DOI
  45. 2015, GLP-1 increases pre-ovulatory LH source and the number of mature follicles as well as synchronizing the onset of puberty in female rats, Endocrinology, 156, 4226, 10.1210/en.2014-1978 · DOI · Paper page
  46. 2016, Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study, Experimental and Therapeutic Medicine, 11, 1194, 10.3892/etm.2016.3081 · DOI · Paper page
  47. 2016, Randomized trial of a lifestyle program in obese infertile women, New England Journal of Medicine, 374, 1942, 10.1056/nejmoa1505297 · DOI · Paper page
  48. 2017, Adverse effects of female obesity and interaction with race on reproductive potential, Fertility and Sterility, 107, 868, 10.1016/j.fertnstert.2017.02.114 · DOI · Paper page
  49. 2017, Metformin therapy for the management of infertility in women with polycystic ovary syndrome, British Journal of Obstetrics and Gynaecology: An International Journal of Obstetrics and Gynaecology, 124, 306, 10.1111/1471-0528.14764 · DOI
  50. 2011, The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study. Society for Assisted Reproductive Technology writing group, Fertility and Sterility, 96, 820, 10.1016/j.fertnstert.2011.07.1100 · DOI

Cited by

See all 237

Metadata

Authors
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E.
Affiliations
  • 1Division of Obstetrics and Gynecology, Department of Human Reproduction
  • Ljubljana University Medical Centre (SI)
  • 2Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
Venue
European Journal of Endocrinology
Published
2018-07
Volume
179
Issue
1
Pages
1-11
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2799507126
Cited by
204
References
46
Citations by year
2026: 41 · 2025: 47 · 2024: 35 · 2023: 23 · 2022: 24 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 1
FWCI
9.07
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
Keywords
liraglutide, polycystic ovary syndrome, obesity, metformin, poor ovarian response, preconception interventions, GLP-1 receptor agonists, weight loss, infertility, endometrial receptivity
MeSH terms
Liraglutide, Adult, Drug Therapy, Combination, Female, Fertilization in Vitro, Humans, Hypoglycemic Agents, Infertility, Female, Metformin, Obesity, Ovulation Induction, Pilot Projects, Polycystic Ovary Syndrome, Pregnancy, Treatment Outcome, Pregnancy Rate, Sperm Injections, Intracytoplasmic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. https://app.cochat.ai/papers/10.1530/eje-18-0175
The paper
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018). Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European Journal of Endocrinology. https://doi.org/10.1530/eje-18-0175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.